Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers



Status:Completed
Conditions:Infectious Disease, Infectious Disease, Hematology
Therapuetic Areas:Hematology, Immunology / Infectious Diseases
Healthy:No
Age Range:Any
Updated:5/19/2018
Start Date:June 27, 2014
End Date:July 4, 2017

Use our guide to learn which trials are right for you!

A Randomized, Double-blind, Placebo Controlled Study of Canakinumab in Patients With Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), With Subsequent Randomized Withdrawal/Dosing Frequency Reduction and Open-label Long-term Treatment Epochs

This study is to determine whether canakinumab is able to induce and maintain a clinically
meaningful reduction of disease activity in participants with Hereditary Periodic Fevers
(HPF) compared to placebo.

This study consists of 3 randomized cohorts (one per condition of colchicine
resistant/intolerant Familial Mediterranean Fever (crFMF), Hyper Immunoglobulin D Syndrome
(also known as mevalonate kinase deficiency (HIDS/MKD), and Tumor Necrosis Factor Receptor
Associated Periodic Syndrome (TRAPS), and 4 study epochs:

1. Epoch 1: a screening epoch to assess participant's eligibility;

2. Epoch 2: a randomized treatment epoch of 16 weeks where participants are randomized to
canakinumab 150 mg every 4 weeks (q4w) or to placebo to obtain efficacy and safety data
in a double-blind placebo controlled parallel-arm setting. This epoch contained 2
possible escape options :

1. early blinded escape option for non responders from Day 8 to Day 28 with here an
add-on dose of 150mg canakinumab followed by blinded uptitration at the next
scheduled visit (Day 29)

2. late unblinded escape option for non responders from Day 29 to Day 112; with
open-label uptitration

3. Epoch 3: a randomized withdrawal epoch of 24 weeks where canakinumab responders from the
randomized treatment epoch were re-randomized to canakinumab 150mg q8w or placebo to
assess the potential for canakinumab to maintain clinical efficacy at a reduced dosing
frequency;

4. Epoch 4: an open-label treatment epoch of 72 weeks to collect long-term

Inclusion Criteria: - Patient's written informed consent (or parent's written informed
consent in case of pediatric patient) at screening - Male and female patients at least 2
years of age at the time of the screening visit. Male and female patients >28 days but <2
years eligible for open label treatment only. - Confirmed diagnosis and active flare at
randomization - CRP >10mg/L at randomization

Exclusion Criteria: - Use of the following therapies (within varying protocol defined
timeframes): Corticosteroids, anakinra, canakinumab, rilonacept, tocilizumab, TNF
inhibitors, abatacept, tofacitinib, rituximab, leflunomide, thalidomide, cyclosporine,
intravenous immunoglobulin, 6-Merceptopurine, azathioprine, cyclophosphamide, or
chlorambucil, any other investigational biologics - History of malignancy of any organ
system (other than localized basal cell carcinoma of the skin or in - situ cervical
cancer), treated or untreated - Significant medical diseases, including but not limited to
the following: a. History of organ transplantation b. Elevated liver enzymes ≥3x ULN d.
Increase in total bilirubin e. Serious hepatic disorder (Child-Pugh scores B or C) f.
Chronic Kidney Disease g. Thyroid disease h. Diagnosis of active peptic ulcer disease i.
Coagulopathy j. Significant CNS effects including vertigo and dizziness - Any conditions or
significant medical problems which immunecompromise the patient and/or places the patient
at unacceptable risk for immunomodulatory therapy - Live vaccinations within 3 months prior
to the start of the trial, during the trial, and up to 3 months following the last dose
We found this trial at
4
sites
Ann Arbor, Michigan 48109
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Cleveland, Ohio 44109
2031
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Edegem, Antwerpen 2650
5591
mi
from 91732
Edegem,
Click here to add this to my saved trials
Los Angeles, California 90095
25
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials